Bankrupt uBiome sells off patents, data for $7M; J&J buys options on Pulmatrix's lung cancer drugs
→ In the final chapter of disgraced gut testing player uBiome’s story, Psomagen has acquired all its key assets in a fire sale, including 246 microbiome patents, anonymized data, nearly 300,000 samples and equipment from uBiome’s lab in San Francisco. Psomagen is the Rockville, MD-based unit of Korean sequencing company Macrogen. For an idea of just how low the once high-flying startup has sunk since the FBI launched an investigation over its business practices, here’s the kick: “The acquisition price is USD 7.05 million, corresponding to 1% of uBiome’s estimated corporate value.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.